A toxicologist's guide to the preclinical assessment of hepatic microsomal enzyme induction

Toxicology Mechanisms and Methods

Volumn 16, Issue 7, 2006, Pages 385-394

  Amacher, David ^a  

^a PFIZER INC   (United States)

Author keywords

Cytochrome P450; Enzyme Induction; Liver; Preclinical Toxicology Studies

Indexed keywords

1 AMINOBENZOTRIAZOLE; 16ALPHA CYANOPREGNENOLONE; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; BETA NAPHTHOFLAVONE; CORTICOSTEROID; CYPROTERONE; CYTOCHROME P450; DEXAMETHASONE; DOXYLAMINE; ERYTHROMYCIN; FURAFYLLINE; IMIDAZOLE DERIVATIVE; ISONIAZID; ISOSAFROLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; PD 138142 15; PHENOBARBITAL; PHENYTOIN; PYRROLE DERIVATIVE; QUINIDINE; RIFAMPICIN; SPIRONOLACTONE; STEROID; TERFENADINE; TIENILIC ACID; TROLEANDOMYCIN; UNINDEXED DRUG; XENOBIOTIC AGENT;

AMINO ACID SEQUENCE; BIOLOGICAL ACTIVITY; CATALYSIS; CLINICAL ASSESSMENT; DETOXIFICATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; ENZYME INDUCTION; HOMEOSTASIS; HUMAN; LIVER MICROSOME; LIVER MICROSOME METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TOXICOLOGY; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

MAMMALIA; RODENTIA;

EID: 33746297342     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.1080/15376510600783791     Document Type: Review

References (124)

1. Amacher, D. E., Schomaker, S. J., and Burkhardt, J. E. 2001. The relationship among microsomal enzyme induction, liver weight and histological change in beagle dog toxicology studies. Food Chem. Toxicol. 39:817-825.
2. Amacher, D. E., Schomaker, S. J., and Burkhardt, J. E. 1998a. The relationship among microsomal enzyme induction, liver weight and histological change in rat toxicology studies. Food Chem. Toxicol. 36:831-839.
3. Amacher, D. E., and Schomaker, S. J. 1998b. Ethylmorphine N-demethylase activity as a marker for cytochrome P450 CYP3A activity in rat hepatic microsomes. Toxicol. Lett. 94:115-125.
4. Amacher, D. E., Schomaker, S. J., Boldt, S. E., and Mirsky, M. 2006. The relationship among microsomal enzyme induction, liver weight, and histological change in cynomolgus monkey toxicology studies. Food Chem. Toxicol. 44:528-537.
5. Badawi, A. F., Cavalieri, E. L., and Rogan, E. G. 2000. Effect of chlorinated hydrocarbons on expression of cytochrome P450 1A1, 1A2 and 1B1 and 2- and 4-hydroxylation of 17beta-estradiol in female Sprague-Dawley rats. Carcinogenesis 21:1593-1599.
6. Barbier, O., Torra, I. P., Sirvent, A., Claudel, T., Blanquart, C., Duran-Sandoval, D., Kuipers, F., Kosykh, V., Fruchart, J. C., and Staels, B. 2003a. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 124:1926-1940.
7. Barbier, O., Villeneuve, L., Bocher, V., Fontaine, C., Torra, I. P., Duhem, C., Kosykh, V., Fruchart, J. C., Guillemette, C., and Staels, B. 2003b. The UDP-glucuronosyltransferase 1A9 enzyme is aperoxisome proliferator-activated receptor alpha and gamma target gene. J. Biol. Chem. 278:13975-13983.
8. Bock, K. W., Gschaidmeier, H., Heel, H., Lehmkoster, T., Munzel, P. A., Raschko, F., and Bock-Hennig, B. 1998. AH receptor-controlled transcriptional regulation and function of rat and human UDP-glucuronosyltransferase isoforms. Adv Enzyme Regul. 38:207-222.
9. Bogaards, J. J., Bertrand, M., Jackson, P., Oudshoorn, M. J., Weaver, R. J., van Bladeren, P. J., and Walther, B. 2000. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131-1152.
10. Bouwman, C. A., Van Dam, E., Fase, K. M., Koppe, J. G., Seinen, W., Thijssen, H. H., Vermeer, C., and Van den Berg, M. 1999. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin or 2,2′,4,4′,5,5′- hexachlorobiphenyl on vitamin K-dependent blood coagulation in male and female WAG/Rij-rats. Chemosphere 38:489-505.
11. Boll, M., Weber, L. W., Font, M., and Stampfl, A. 1998. The enzyme inducers 3-methylcholanthrene and phenobarbital affect the activities of glucocorticoid hormone-regulated enzymes in rat liver and kidney. Toxicology 126:127-136.
12. Bookstaff, R. C., Murphy, V. A., Skare, J. A., Minnema, D., Sanzgiri, U., and Parkinson, A. 1996. Effects of doxylamine succinate on thyroid hormone balance and enzyme induction in mice. Toxicol. Appl. Pharmacol. 141:584-594.
13. Buhler, R., Lindros, K. O., Nordling, A., Johansson, I., and Ingelman-Sundberg, M. 1992. Zonation of cytochrome P450 isozyme expression and induction in rat liver. Eur. J. Biochem. 204:407-412.
14. Chen, C., Staudinger, J. L., and Klaassen, C. D. 2003. Nuclear receptor, pregname X receptor, is required for induction of UDP-glucuronosyltranferases in mouse liver by pregnenolone-16 alpha-carbonitrile. Drug Metab. Dispo. 31:908-915.
15. Chen, Y. L., Florentin, I., Batt, A. M., Ferrari, L., Giroud, J. P., and Chauvelot-Moachon, L. 1992. Effects of interleukin-6 on cytochrome P450-dependent mixed-function oxidases in the rat. Biochem. Pharmacol. 44:137-148.
16. Comer, C. P., Chengelis, C. P., Levin, S., and Kotsonis, F. N. 1985. Changes in thyroidal function and liver UDPglucuronosyltransferase activity in rats following administration of a novel imidazole (SC-37211). Toxicol. Appl. Pharmacol. 80:427-436.
17. Coulson, M., Gibson, G. G., Plant, N., Hammond, T., and Graham, M. 2003. Lansoprazole increases testosterone metabolism and clearance in male Sprague-Dawley rats: implications for Leydig cell carcinogenesis. Toxicol. Appl. Pharmacol. 192:154-163.
18. Desta, Z., Soukhova, N. V., and Flockhart, D. A. 2001. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrobial Agents Chemother 45:382-392.
19. Diamond, S., Rakestraw, D., O'Neil, J., Lam, G. N., and Christ, D. D. 1994. Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab. Dispo. 22:65-73.
20. Dohler, K. D., Wong, C. C., and von zur Muhlen, A. 1979. The rat as model for the study of drug effects on thyroid function: consideration of methodological problems. Pharmacol. Ther. - Part B: Gen. Systematic Pharmacol. 5:305-318.
21. Donato, M. T., Jimenez, N., Castell, J. V., and Gomez-Lechon, M. J. 2004. Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab. Dispo. 32:699-706.
22. Dvorak, Z., Modriansky, M., Pichard-Garcia, L., Balaguer, P., Vilarem, M. J., Ulrichova, J., Maurel, P., and Pascussi, J. M. 2003. Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol. Pharmacol. 64:160-169.
23. Eeckhoudt, S. L., Desager, J. P., Robert, A. R., Leclercq, I., Verbeeck, R. K., and Horsmans, Y. 2001. Midazolam and cortisol metabolism before and after CYP3A induction in humans. Int. J. Clin. Pharmacol. Ther. 39:293-299.
24. Embola, C. W., Sohn, O. S., Fiala, E. S., and Weisburger, J. H. 2002. Induction of UDP-glucuronosyltransferase 1 (UDP-GT1) gene complex by green tea in male F344 rats. Food Chem. Toxicol. 40:841-844.
25. Feuer, G. 1983. Drug control of steroid metabolism by the hepatic endoplasmic reticulum. Drug Metab. Rev. 14:1119-1144.
26. Franklin, M. R. 1993. Induction of rat liver drug-metabolizing enzymes by heterocycle-containing mono-, di-, tri- and tetra-arylmethanes. Biochem. Pharmacol. 46:683-689.
27. Frye, R. F., Matzke, G. R., Adedoyin, A., Porter, J. A., and Branch, R. A. 1997. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin. Pharmacol. Ther. 62:365-376.
28. Fujisaki, H., Mise, M., Ishii, Y., Yamada, H., and Oguri, K. 1994. Strychnine and brucine as the potent inducers of drug metabolizing enzymes in rat liver: different profiles from phenobarbital on the induction of cytochrome P450 and UDP-glucuronosyltransferase. J. Pharmacol. Exp. Ther. 268:1024-1031.
29. Gagne, D., Labhilili, M., and Pons, M. 1988. Description and analysis of differential sensitivity to glucocorticoids in Fao cells. J. Steroid Biochem. 31:917-925.
30. Gibson, G. G., Plant, N. J., Swales, K. E., Ayrton, A., and El-Sankary, W. 2002. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:165-206.
31. Gonzalez, F. J. 1990. Molecular genetics of the P-450 superfamily. Pharmacol. Ther. 45:1-38.
32. Groen, K., Breimer, D. D., Jansen, E. J., and van Bezooijen, C. F. 1994. The influence of aging on the metabolism of simultaneously administered hexobarbital enantiomers and antipyrine before and after phenobarbital induction in male rats: a longitudinal study. J. Pharmacol. Exp. Ther. 268:531-536.
33. Graham, R. A., Downey, A., Mudra, D., Krueger, L., Carroll, K., Chengelis, C., Madan, A., and Parkinson, A. 2002. In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metab. Dispo. 30:1206-1213.
34. Handschin, C., and Meyer, U. A. 2005. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch. Biochem. Biophys. 433:387-396.
35. Huang, L., Zhao, A., Lew, J. L., Zhang, T., Hrywna, Y., Thompson, J. R., de Pedro, N., Royo, I., Blevins, R. A., Pelaez, F., Wright, S. D., and Cui, J. 2003. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J. Biol. Chem. 278:51085-51090.
36. Halpert, J. R. 1995. Structural basis of selective cytochrome P450 inhibition. Annu. Rev. Pharmacol. Toxicol. 35:29-53.
37. Huitema, A. D., Mathot, R. A., Tibben, M. M., Rodenhuis, S., and Beijnen, J. H. 2001. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. J. Pharmacokinet. Pharmacodyn. 28:211-230.
38. Ioannides, C. 1996. Cytochrome P450 Metabolic and Toxicological Aspects, CRC Press, New York.
39. Jacobs, M. N., Dickins, M., and Lewis, D. F. 2003. Homology modelling of the nuclear receptors: human oestrogen receptorbeta (hERbeta), the human pregnane-X-receptor (PXR), the Ah receptor (AhR) and the constitutive androstane receptor (CAR) ligand binding domains from the human oestrogen receptor alpha (hERalpha) crystal structure, and the human peroxisome proliferator activated receptor alpha (PPARalpha) ligand binding domain from the human PPARgamma crystal structure. J. Steroid Biochem. Mol. Biol. 84:117-132.
40. Jayyosi, Z., Muc, M., Erick, J., Thomas, P. E., and Kelley, M. 1996. Catalytic and immunochemical characterization of cytochrome P450 isozyme induction in dog liver. Fundam. Appl. Toxicol. 31:95-102.
41. Jirtle, R. L., Meyer, S. A., and Brockenbrough, J. S. 1991. Liver tumor promoter phenobarbital: a biphasic modulator of hepatocyte proliferation. Prog. Clin. Biol. Res. 369:209-216.
42. Jones, S. A., Moore, L. B., Shenk, J. L., Wisely, G. B., Hamilton, G. A., McKee, D. D., Tomkinson, N. C., LeCluyse, E. L., Lambert, M. H., Willson, T. M., Kliewer, S. A., and Moore, J. T. 2000. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 14:27-39.
43. Jurima-Romet, M., Crawford, K., Cyr, T., and Inaba, T. 1994. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab. Dispo. 22:849-857.
44. Kato, R., and Yamazoe, Y. 1992. Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. Toxicol. Lett. 64-65 Spec No: 661-667.
45. Keller, N., Richardson, U. I., and Yates, F. E. 1969. Protein binding and the biological activity of corticosteroids: in vivo induction of hepatic and pancreatic alanine aminotransferases by corticosteroids in normal and estrogen-treated rats. Endocrinology 84:49-62.
46. Kenyon, K. W., and Nappi, J. M. 2003. Bosentan for the treatment of pulmonary arterial hypertension. Ann. Pharmacother. 37:1055-1062.
47. Kerbusch, T., Jansen, R. L., Mathot, R. A., Huitema, A. D., Jansen, M., van Rijswijk, R. E., and Beijnen, J. H. 2001. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin. Pharmacol. Ther. 70:132-141.
48. Kiernan, T. W., Luisada-Opper, A., and Ertel, N. H. 1981. Hepatic microsomal induction in rat liver: heterogeneity of response. J. Clin. Pharmacol. 21:280-283.
49. Kim, Y., Sills, R. C., and Houle, C. D. 2005. Overview of the molecular biology of hepatocellular neoplasms and hepatoblastomas of the mouse liver. Toxicol. Pathol. 33:175-180.
50. King, C. D., Rios, G. R., Green, M. D., and Tephly, T. R. 2000. UDP-glucuronosyltransferases. Curr. Drug Metab. 1:143-161.
51. King, T. J., and Lampe, P. D. 2004. The gap junction protein connexin32 is a mouse lung tumor suppressor. Cancer Res. 64:7191-7196.
52. Landes, N., Birringer, M., and Brigelius-Flohe, R. 2003. Homologous metabolic and gene activating routes for vitamins E and K. Mol. Aspects Med. 24:337-344.
53. Ledirac, N., de Sousa, G., Fontaine, F., Agouridas, C., Gugenheim, J., Lorenzon, G., and Rahmani, R. 2000. Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin. Drug Metab. Dispo. 28:1391-1393.
54. Lewis, D. F. 2001. Guide to Cytochromes P450 Structure and Function, Taylor & Francis, New York.
55. Li, D. N., Pritchard, M. P., Hanlon, S. P., Burchell, B., Wolf, C. R., and Friedberg, T. 1999. Competition between cytochrome P-450 isozymes for NADPH-cytochrome P-450 oxidoreductase affects drug metabolism. J. Pharmacol. Exp. Ther. 289:661-667.
56. Lindros, K. O. 1997. Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver. Gen. Pharmacol. 28:191-196.
57. Lubet, R. A., Nims, R. W., Ward, J. M., Rice, J. M., and Diwan, B. A. 1989. Induction of cytochrome P450 and its relationship to liver tumor promotion. J. Am. Coll. Toxicol. 8:259-268.
58. Marshall, W. J. 1978. Enzyme induction by drugs. Its relevance to clinical biochemistry. Ann. Clin. Biochem. 15:55-64.
59. Matzke, G. R., Frye, R. F., Early, J. J., Straka, R. J., and Carson, S. W. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 20:182-190.
60. McClain, R. M. 1989. The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: implications for thyroid gland neoplasia. Toxicol. Pathol. 17:294-306.
61. Mirochnick, M., Clarke, D. F., and Dorenbaum, A. 2000. Nevirapine: pharmacokinetic considerations in children and pregnant women. Clin. Pharmacokinet. 39:281-293.
62. Moennikes, O., Buchmann, A., Romualdi, A., Ott, T., Werringloer, J., Willecke, K., and Schwarz, M. 2000. Lack of phenobarbital-mediated promotion of hepatocarcinogenesis in connexin32-null mice. Cancer Res. 60:5087-5091.
63. Moore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., Goodwin, B., Liddle, C., Blanchard, S. G., Willson, T. M., Collins, J. L., and Kliewer, S. A. 2000. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275:15122-15127.
64. Muntane-Relat, J., Ourlin, J. C., Domergue, J., and Maurel, P. 1995. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 22(4 Pt 1):1143-1153.
65. Muller, P. B., Taboada, J., Hosgood, G., Partington, B. P., VanSteenhouse, J. L., Taylor, H. W., and Wolfsheimer, K. J. 2000. Effects of long-term phenobarbital treatment on the liver in dogs. J. Vet. Intern. Med. 14:165-171.
66. Murray, M., and Reidy, G. F. 1990. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev. 42:85-101.
67. Nebert, D. W., Adesnik, M., Coon, M. J., Estabrook, R. W., Gonzalez, F. J., Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., Kemper, B., Levin, W., Phillips, I. R., Sato, R., and Waterman, M. R. 1987. The P450 gene superfamily: recommended nomenclature. DNA. 6:1-11.
68. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C., and Nebert, D. W. 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
69. Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. P., Estabrook, R. W., Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O., Okuda, K., and Nebert, D. W. 1993. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12:1-51.
70. Neveu, M. J., Babcock, K. L., Hertzberg, E. L., Paul, D. L., Nicholson, B. J., and Pitot, H. C. 1994. Colocalized alterations in connexin32 and cytochrome P450IIB1/2 by phenobarbital and related liver tumor promoters. Cancer Res. 54:3145-3152.
71. Nishibe, Y., Wakabayashi, M., Harauchi, T., and Ohno, K. 1998. Characterization of cytochrome P450 (CYP3A12) induction by rifampicin in dog liver. Xenobiotica 28:549-557.
72. O'Brien, P. J., Slaughter, M. R., Polley, S. R., and Kramer, K. 2002. Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Lab. Anim. 36:313-321.
73. Okey, A. B. 1990. Enzyme induction in the cytochrome P-450 system. Pharmacol. Ther. 45:241-298.
74. Oinonen, T., Saarikoski, S., Husgafvel-Pursiainen, K., Hirvonen, A., and Lindros, K. O. 1994. Pretranslational induction of cytochrome P4501A enzymes by beta-naphthoflavone and 3-methylcholanthrene occurs in different liver zones. Biochem. Pharmacol. 48:2189-2197.
75. Ortiz de Montellano, P. R., Mico, B. A., Mathews, J. M., Kunze, K. L., Miwa, G. T., and Lu, A. Y. 1981. Selective inactivation of cytochrome P-450 isozymes by suicide substrates. Arch. Biochem. Biophys. 210:717-728.
76. Palmer, C. N., Coate, P. J., Davies, S. E., Shephard, E. A., and Phillips, I. R. 1992. Localization of cytochrome P-450 gene expression in normal and diseased human liver by in situ hybridization of wax-embedded archival material. Hepatology 16:682-687.
77. Pascussi, J. M., Gerbal-Chaloin, S., Drocourt, L., Maurel, P., and Vilarem, M. J. 2003. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim. Biophys. Acta. 1619:243-253.
78. Rendic, S. 2002. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34:83-448.
79. Renwick, A. B., Lavignette, G., Worboy, P. D., Williams, B., Surry, D., Lewis, D. F., Price, R. J., Lake, B. G., and Evans, D. C. 2001. Evaluation of 7-benzyloxy-4-trifluoromethylcoumarin, some other 7-hydroxy-4- trifluoromethylcoumarin derivatives and 7-benzyloxyquinoline as fluorescent substrates for rat hepatic cytochrome P450 enzymes. Xenobiotica 31:861-878.
80. Ritter, J. K., and Franklin, M. R. 1987. Induction and inhibition of rat hepatic drug metabolism by N-substituted imidazole drugs. Drug Metab. Dispo. 15:335-343.
81. Robertson, D. G., Krause, B. R., Welty, D. F., Wolfgang, G. H., Graziano, M. J., Pilcher, G. D., and Urda, E. 1995. Hepatic microsomal induction profile of carbamic acid [[2,6-bis(1- methylethyl)phenoxy] sulfonyl]-2,6-bis(1- methylethyl) phenyl ester, monosodium salt (PD138142-15), a novel lipid regulating agent. Biochem. Pharmacol. 49:799-808.
82. Rodrigues, A. D., and Wong, S. L. 1997. Application of human liver microsomes in metabolism-based drug-drug interactions: in vitro-in vivo correlations and the Abbott Laboratories experience. Adv. Pharmacol. 43:65-101.
83. Roffey, S. J., Cole, S., Comby, P., Gibson, D., Jezequel, S. G., Nedderman, A. N., Smith, D. A., Walker, D. K., and Wood, N. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispo. 31:731-741.
84. Rosalki, S. B. 1976. Plasma enzyme changes and their interpretation in patients receiving anticonvulsant and enzyme induction drugs. In: Richens, A., and Woodford, F. P. (Eds.), Anticonvulsant Drugs and Enzyme Induction, Elsevier, Amsterdam, Vol 27.
85. Rosenbrock, H., Hagemeyer, C. E., Singec, I., Knoth, R., and Volk, B. 1999. Testosterone metabolism in rat brain is differentially enhanced by phenytoin-inducible cytochrome P450 isoforms. J. Neuroendocrinol. 11:597-604.
86. Runge, D. M., Stock, T. W., Lehmann, T., Taege, C., Bernauer, U., Stolz, D. B., Hofmann, S., and Foth, H. 2001. Expression of cytochrome P450 2E1 in normal human bronchial epithelial cells and activation by ethanol in culture. Arch. Toxicol. 75:335-345.
87. Salphati, L., and Benet, L. Z. 1998. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem. Pharmacol. 55:387-395.
88. Sanders, J. E., Eigenberg, D. A., Bracht, L. J., Wang, W. R., and van Zwieten, M. J. 1988. Thyroid and liver trophic changes in rats secondary to liver microsomal enzyme induction caused by an experimental leukotriene antagonist (L-649,923). Toxicol. Appl. Pharmacol. 95:378-387.
89. Schomaker, S. J., Boldt, S. E., and Amacher, D. E. 2004. The effects of five human microsomal enzyme inhibitors on the cytochrome P450 system of the CD rat liver. (abstract). Drug Metab. Rev. 36:276.
90. Schomaker, S. J., and Amacher, D. E. HPLC Analysis of Progesterone Metabolism Catalyzed by Rat Hepatic P450 Isozymes. (Abstract). Proceedings, International Society for the Study of Xenobiotics. 1999. Vol 15, 9th North American Meeting, Nashville, TN.
91. Schuetz, E. G. 2001. Induction of cytochromes P450. Curr. Drug Metab 2:139-147.
92. Schuetz, E. G., Schmid, W., Schutz, G., Brimer, C., Yasuda, K., Kamataki, T., Bornheim, L., Myles, K., and Cole, T. J. 2000. The glucocorticoid receptor is essential for induction of cytochrome P-4502B by steroids but not for drug or steroid induction of CYP3A or P-450 reductase in mouse liver. Drug Metab. Dispo. 28:268-278.
93. Schwarz, M., Wanke, I., Wulbrand, U., Moennikes, O., and Buchmann, A. 2003. Role of connexin32 and beta-catenin in tumor promotion in mouse liver. Toxicol. Pathol. 31:99-102.
94. Semler, D. E., Chengelis, C. P., and Radzialowski, F. M. 1989. The effects of chronic ingestion of spironolactone on serum thyrotropin and thyroid hormones in the male rat. Toxicol. Appl. Pharmacol. 98:263-268.
95. Shen, A. L., and Kasper, C. B. 1993. Protein and gene structure and regulation of NADPH-cytochrome P450 oxidoreductase. In: Shenkman, J. B., and Griem, H. (Eds.), Cytochrome P-450, Springer-Verlag, Berlin, Vols. 35-59.
96. Sharer, J. E., Shipley, L. A., Vandenbranden, M. R., Binkley, S. N., and Wrighton, S. A. 1995. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and Cynomolgus monkey. Drug Metab. Dispo. 23:1231-1241.
97. Shimada, T., Mimura, M., Inoue, K., Nakamura, S., Oda, H., Ohmori, S., and Yamazaki, H. 1997. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch. Toxicol. 71:401-408.
98. Shoda, T., Mitsumori, K., Onodera, H., Toyoda, K., Uneyama, C., Takada, K., and Hirose, M. 2000. Liver tumor-promoting effect of beta-naphthoflavone, a strong CYP 1A1/2 inducer, and the relationship between CYP 1A1/2 induction and Cx32 decrease in its hepatocarcinogenesis in the rat. Toxicol. Pathol. 28:540-547.
99. Shoda, T., Mitsumori, K., Onodera, H., Toyoda, K., Uneyama, C., Imazawa, T., and Hirose, M. 1999. The relationship between decrease in Cx32 and induction of P450 isozymes in the early phase of clofibrate hepatocarcinogenesis in the rat. Arch. Toxicol. 73:373-380.
100. Simonsson, U. S., Jansson, B., Hai, T. N., Huong, D. X., Tybring, G., and Ashton, M. 2003. Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin. Pharmacol. Ther. 74:32-43.
101. Sladek, R., and Giguere, V. 2000. Orphan nuclear receptors: an emerging family of metabolic regulators. Adv. Pharmacol. 47:23-87.
102. Sonderfan, A. J., Arlotto, M. P., Dutton, D. R., McMillen, S. K., and Parkinson, A. 1987. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys. 255:27-41.
103. Sohn, H. O., Lim, H. B., Lee, Y. G., Lee, D. W., and Lee, K. B. 1994. Modulation of cytochrome P-450 induction by long-term food restriction in male rats. Biochem. Mol. Biol. Int. 32:889-896.
104. Stevens, J. C., Shipley, L. A., Cashman, J. R., Vandenbranden, M., and Wrighton, S. A. 1993. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metab. Dispo. 21:753-760.
105. Strolin Benedetti, M., and Dostert, P. 1994. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ. Health Perspect. 102(Suppl 9):101-105.
106. Sugatani, J., Nishitani, S., Yamakawa, K., Yoshinari, K., Sueyoshi, T., Negishi, M., and Miwa, M. 2005. Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Mol. Pharmacol. 67:845-855.
107. Swinney, D. C., Ryan, D. E., Thomas, P. E., and Levin, W. 1987. Regioselective progesterone hydroxylation catalyzed by eleven rat hepatic cytochrome P-450 isozymes. Biochemistry 26:7073-7083.
108. Takikawa, H. 2002. Hepatobiliary transport of bile acids and organic anions. J. Hepato-Biliary-Pancreat. Surg 9:443-447.
109. Testa, B., and Jenner, P. 1981. Inhibitors of cytochrome P-450s and their mechanism of action. Drug Metab. Rev. 12:1-117.
110. Totis, M., Magdalou, J., Fournel-Gigleux, S., Batt, A. M., and Siest, G. 1989. Induction of UDP-glucuronosyltransferase isozymes in male and female rat liver microsomes by an isoquinoleine derivative (52028 RP). Biochem. Pharmacol. 38:3634-3638.
111. Tucker, G. T., Houston, J. B., and Huang, S. M. 2001. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br. J. Clin. Pharmacol. 52:107-117.
112. Ueda, A., Hamadeh, H. K., Webb, H. K., Yamamoto, Y., Sueyoshi, T., Afshari, C. A., Lehmann, J. M., and Negishi, M. 2002. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol. Pharmacol. 61:1-6.
113. van der Hoeven, T. 1981. Testosterone oxidation by rat liver microsomes: effects of phenobarbital pretreatment and the detection of seven metabolites by HPLC. Biochem. Biophys. Res. Commun. 100:1285-1291.
114. Waechter, F., Beilstein, P., Burger, A. G., O'Connell, M., Fabreguettes, C., Forster, R., and Weideli, H. 1999. Subchronic toxicity study with ethylene-bis-(oxyethylene)-bis-(3-tert-butyl-4-hydroxy-5-methylhydro cin namate) in the cynomolgus monkey: lack of stimulation of the pituitary-thyroid-liver axis. Toxicol. Sci. 51:36-43.
115. Wang, H., and LeCluyse, E. L. 2003. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 42:1331-1357.
116. Watkins, J. B., and Klaassen, C. D. 1982. Induction of UDP-glucuronosyltransferase activities in Gunn, heterozygous, and Wistar rat livers by pregnenolone-16 alpha-carbonitrile. Drug Metab. Dispo. 10:590-594.
117. Wensing, G., Neumann, U., Ohnhaus, E. E., and Heidemann, H. T. 1990. Effect of antipyrine and phenobarbital on renal gamma-glutamyltransferase excretion in human urine. Clin. Pharmacol. Ther. 48:575-581.
118. Wilson, A. C., and Park, B. K. 1984. The effect of phenobarbitone pre-treatment on vitamin K1 disposition in the rat and rabbit. Biochem. Pharmacol. 33:141-146.
119. Wong, B. K., Fei, P., and Kong, A. N. 1995. Differential induction of UDP-glucuronosyltransferase activity and gene expression in rat liver. Pharm. Res. 12:1105-1108.
120. Yoo, J. S., Ning, S. M., Pantuck, C. B., Pantuck, E. J., and Yang, C. S. 1991. Regulation of hepatic microsomal cytochrome P450IIE1 level by dietary lipids and carbohydrates in rats. J. Nutr. 121:959-965.
121. Yuan, R., Parmelee, T., Balian, J. D., Uppoor, R. S., Ajayi, F., Burnett, A., Lesko, L. J., and Marroum, P. 1999. In vitro metabolic interaction studies: experience of the Food and Drug Administration. Clin. Pharmacol. Ther. 66:9-15.
122. Yamamoto, Y., Moore, R., Goldsworthy, T. L., Negishi, M., and Maronpot, R. R. 2004. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res. 64:7197-7200.
123. Zbinden, G. 1987. Assessment of hyperplastic and neoplastic lesions of the thyroid gland. TIPS 8:511-514.
124. Zhukov, A., and Ingelman-Sundberg, M. 1999. Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanol-inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor NADPH-cytochrome P450 reductase. Biochem. J 340(Pt 2):453-458.